Health Trials

Refractory Hepatocellular Carcinoma

3

Review clinical trials related to Refractory Hepatocellular Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

Participants needed: 147
Trial details
Phase: Phase 1, Phase 2Age: 12-30Biological sex: AllType: InterventionalSponsor: Children's Oncology GroupUpdated: May 5, 2026Locations: 21
Eligibility criteria

PART A: Patients must be >= 12 months and =< 21 years of age at the time of stud... [+39]

Pregnant or breast-feeding women will not be entered on this study because there... [+17]

Read more
Status: Recruiting

Ligufalimab and Cadonilimab in Advanced Liver Cancers

The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.

Participants needed: 64
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Texas Southwestern Medical CenterUpdated: Feb 27, 2026Locations: 1
Eligibility criteria

Histological confirmation of specific disease -Cohort A (HCC): Patient must have... [+15]

Prior liver transplant. [+26]

Read more
Status: Not yet recruiting

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Penpulimab in patients with hepatocellular carcinoma after standard treatment failure.

Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Jul 20, 2025
Eligibility criteria

Histologically or cytologically confirmed, or clinically diagnosed (according to... [+8]

History of other malignant tumors with disease-free survival <5 years (except cu... [+3]

Read more